glp 1 agonist addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Five things to know about
Description
2024, doi: 10.1111/dom.15869
Risks and Considerations, While compounded medications can offer some benefits, they also come with significant risks: Lack of Regulation and Testing : Unlike brand-name medications, compounded drugs are not subject to the same testing and FDA approval process
The GLP-1 receptor (GLP-1R), which mediates the biological effects of the hormone with relevance for and beyond CVD, is present across many organs and tissues in humans (Figure 1)
Wireko, A.A
[DOI] [PubMed] [Google Scholar] 73.Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E
